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Abstract
Background: Patients with cancer are at increased risk of drug-drug interactions (DDI), which can increase
treatment toxicity or decrease efficacy. It is especially important to thoroughly screen DDI in oncology clinical trial
subjects to ensure trial subject safety and data accuracy. This study determined the prevalence of potential DDI
involving oral anti-cancer trial agents in subjects enrolled in two SWOG clinical trials.
Methods: Completed SWOG clinical trials of commercially available agents with possible DDI that had complete
concomitant medication information available at enrollment were included. Screening for DDI was conducted
through three methods: protocol-guided screening, Lexicomp® screening, and pharmacist determination of clinical
relevance. Descriptive statistics were calculated.
Results: SWOG trials S0711 (dasatinib, n = 83) and S0528 (everolimus/lapatinib, n = 84) were included. Subjects
received an average of 6.6 medications (standard deviation = 4.9, range 0–29) at enrollment. Based on the clinical
trial protocols, at enrollment 18.6% (31/167) of subjects had a DDI and 12.0% (20/167) had a DDI that violated a
protocol exclusion criterion. According to Lexicomp®, 28.7% of subjects (48/167) had a DDI classified as moderate or
worse, whereas pharmacist review indicated that 7.2% of subjects (12/167) had a clinically relevant interaction. The
majority of clinically relevant DDI identified were due to the coadministration of acid suppression therapies with
dasatinib (83.3%, 10/12).
Conclusions: The high DDI prevalence in subjects enrolled on SWOG clinical trials, including a high prevalence that
violate trial exclusion criteria, support the need for improved processes for DDI screening to ensure trial subject
safety and trial data accuracy.
Keywords: Oncology clinical trial drug interaction
Background
Drug-drug interactions (DDI) can cause treatment to
be unsafe for patients by increasing drug toxicity or
decreasing treatment efficacy [1]. Patients with cancer
have particularly high risk of DDI due to their in-
creasing age, numerous comorbidities and high rates
of polypharmacy [2]. An estimated 16–41% of patients
receiving cancer treatment have a potential DDI [3–
7], which increase risk of severe toxicity nearly three-
fold [8]. DDI can be detected using high performing
DDI screening tools [9] and effectively managed by
incorporating clinical pharmacists or pharmacologists
on the healthcare team [4, 5].
DDI can affect drug levels by altering drug absorption,
distribution, metabolism or excretion or can affect drug
response through mechanistic synergy or antagonism
[1]. Cancer treatment is shifting from primarily infusion-
based treatment towards oral agents [10]. In addition to
the typical concerns with metabolic DDI, oral agents
have additional DDI concerns relating to their need to
be absorbed from the gastrointestinal tract. Intestinal
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absorption of oral agents can be affected by changes in
gastrointestinal pH and activity of uptake transports.
Concomitant administration of gastric acid suppression
such as proton pump inhibitors (PPI) or histamine H2
antagonists (H2RA) with tyrosine kinase inhibitors can
reduce drug absorption decreasing AUC as much as 60%
[11], which decreases systemic exposure and treatment
efficacy [12, 13]. Additionally, these oral agents are often
given daily over an extended period of time increasing
the risk of DDI.
DDI management is particularly critical for subjects
enrolled in oncology clinical trials, within which the ben-
efits and harms of trial agents are determined. Current
processes to detect DDI during trial eligibility screening
are inadequate and lack standardization across sites,
even within the National Cancer Institute’s National
Clinical Trials Network (NCTN) system [14]. Few stud-
ies have examined the prevalence of DDI in oncology
clinical trial subjects [15, 16]. In our prior work, nearly
25% of subjects enrolled on an NCTN clinical trial at
the University of Michigan Rogel Cancer Center were
found to have at least one major or contraindicated DDI
[16]. This high prevalence suggests many DDI are not
being detected and managed during eligibility assess-
ment screening, which raises concerns about trial subject
safety and data accuracy.
Based on the high prevalence of DDI in subjects at
their time of enrollment on NCTN trials at a single in-
stitution, the objective of this study was to determine
the prevalence of DDIs involving trial agents in subjects
at enrollment in multi-center SWOG clinical trials. A
secondary objective was to determine the prevalence of
DDI caused by the addition of medications in subjects
while on SWOG clinical trials.
Methods
Data collection/selection
All closed SWOG clinical trials with available data were
evaluated for inclusion. SWOG clinical trials of commer-
cially available agents that collected comprehensive con-
comitant medication information at the time of
enrollment were eligible for inclusion. Trials were ex-
cluded if the trial agent did not have any possible DDI.
Complete medication lists at enrollment and medication
changes during the trial for each subject were collected
from the existing trial record. Concomitant medications
that were noted to be administered for two or fewer
doses were not included in the total number of medica-
tions a subject was taking or evaluated during DDI
screening.
Protocol-guided screening
Detailed methods for protocol guided screening have
been previously described [16]. Briefly, clinical trial
protocols were reviewed for all language discussing con-
comitant medications with DDI concerns that should be
considered exclusion criteria, medications to avoid, or
medications to use with caution. Medication lists were
compared to this protocol information to determine
whether each subject had a DDI according to protocol-
guided screening for the trial on which they were
enrolled.
Lexicomp® guided screening
Medication lists were screened for major or contraindi-
cated DDI involving the trial agent using Lexicomp®
Drug Interactions. Lexicomp® was selected based on its
strong performance when screening for DDI with oral
chemotherapy [9].
DDI clinical relevance determination
DDI identified by protocol or Lexicomp® guided screen-
ing were manually reviewed by a pharmacist and student
pharmacists for clinical relevance. Clinical relevance was
defined as a DDI that would warrant a drug change or
discontinuation to ensure subject safety and drug effi-
cacy. This process is similar to the process we used in
previous studies to allow for cross-study comparison
[16].
Statistical analysis
The prevalence of DDI by protocol-guided screening,
Lexicomp® guided screening, and clinically relevant DDI
were calculated for each SWOG trial and combined
across trials. The mean, median, and range of medica-
tions per subject was also calculated. Statistical analysis
was performed using R software.
The primary analysis did not count any DDI involving
antacids, as these can be avoided by properly separating
timing of administration. A secondary analysis that in-
cludes antacids as DDI was also conducted since admin-
istration timing information was not available, therefore,
these potential DDI cannot be excluded. The following
were considered antacids: aluminum hydroxide, magne-
sium hydroxide, magnesium carbonate, and calcium car-
bonate dosed as needed.
Results
Protocol characteristics and subjects
Two SWOG trials of commercially available agents that
had potential DDI and concomitant medication lists
were identified. SWOG 0711 (S0711) and 0528 (S0528)
were pharmacokinetic trials of dasatinib and everolimus/
lapatinib, respectively. S0711 started October 2008 and
closed June 2014, and S0528 started September 2006
and closed August 2009. Medications lists were collected
when each trial was conducted as a step within protocol
procedures and were available for retrospective review
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for all subjects enrolled on S0711 (n = 83) and S0528
(n = 84). At enrollment subjects were receiving 0–29
concomitant medications (mean: 6.6, standard deviation:
4.9). Medication additions during the trial occurred in
40.7% (68/167) of subjects, with a mean of 1.9 (standard
deviation = 4.8, range 0–23) medications added per
subject.
DDI detected by protocol-guided screening
Protocol-specified concomitant medications that would
warrant subject exclusion, or medications that should be
avoided or used with caution are shown in Table 1. At
the time of enrollment to either of the two trials, 18.6%
(31/167, Fig. 1a) of subjects had at least one DDI based
on protocol-guidance, the majority of which violated ex-
clusion criteria (12.0% of subjects, 20/167). In the sec-
ondary analysis including DDI with antacids, 24.6% (41/
167) of subjects had at least one DDI and 17.4% (29/
167) of subjects had a DDI that violated exclusion cri-
teria. During the trial, 9.6% of subjects (16/167) had a
medication added that was considered a DDI based on
protocol guidance. A total of 8.4% (14/167) of subjects
had a medication added that violated exclusion criteria.
In the S0711 trial, 18.1% (15/83) of subjects had at
least one DDI at enrollment based on the trial protocol,
and 12.0% (10/83) of subjects had a DDI that was a vio-
lation of an exclusion criterion (Table 2). Most of these
exclusion criteria violations were due to the combination
of dasatinib with a PPI (80%, 8/10, Online Resource 1)
and the rest were due to an H2RA (20%, 2/10). Including
antacids as DDI, 22.9% (19/83) of subjects had an exclu-
sion criterion violation at enrollment. A medication that
violated an exclusion criterion was added during the trial
in 13.3% (11/83) of subjects, all of which were PPI.
In the S0528 trial, 20.2% (17/84) of subjects had at
least one potential DDI at enrollment based on
protocol-guided screening (Table 2). The majority of
DDI violated protocol exclusion criteria (11.9%, 10/84);
these were nearly evenly split between the combination
of lapatinib with PPIs (60.0%, 6/10) and H2RAs (50.0%,
5/10). No subjects were taking antacids at baseline, so
the results of the secondary analysis were the same as
the primary analysis. Three subjects had a protocol iden-
tified DDI added while on trial (3.6%, 3/84) and each of
these DDI violated an exclusion criterion.
DDI detected by Lexicomp®
At baseline, 28.7% of subjects (48/167, Fig. 1b) had at
least one major or contraindicated DDI detected by Lex-
icomp®. The majority of these interactions were detected
in S0711 and were due to the combination of dasatinib
with acid suppression therapies and/or acetaminophen
(acid suppression only: 13/46, acetaminophen only: 20/
46, both: 11/46, other: 2/46). During the trials 10.2%
(17/167) of subjects had a medication added that caused
a DDI, all of which were S0711 subjects.
Clinically relevant DDI
In the primary analysis, 7.2% of subjects (12/167) had at
least one DDI at enrollment that was considered to be
clinically relevant, and this increased to 12.6% (21/167)
when including antacids in the secondary analysis. The
majority of these clinically relevant interactions (83.3%,
10/12) were between dasatinib and PPIs or H2RAs. The
clinically relevant interactions with lapatinib/everolimus
were with verapamil (n = 1) and fluconazole (n = 1). The
interaction of dasatinib with acid suppression therapy
was considered clinically relevant, so 6.6% (11/167) of
subjects, all on S0711, had a drug added during the trial
that led to a clinically relevant DDI.
Discussion
Patients with cancer have a high prevalence of DDI [3–
6] that can decrease patient safety and increase toxicity
[1]. Oncology clinical trial subjects also have high preva-
lence of DDI due to the lack of standardized screening
procedures [14]. In our previous work, approximately
25% of subjects enrolled on an NCTN trial at a single-
site had DDI at enrollment [16]. This follow-up analysis
of subjects enrolled on SWOG trials across sites con-
firmed a high prevalence of DDI, though the exact esti-
mate depends on whether the determination is based on
the protocol (19–25%), is limited to protocol exclusion
criteria (12%), or is based on Lexicomp® (29%) or clinical
judgement (7%). This study also found inadequacies in
DDI screening for drugs added while a subject is on a
clinical trial.
The prevalence of at least one major or contraindi-
cated DDI at enrollment detected by Lexicomp® (29%) is
similar to the prevalence detected in subjects enrolling
on NCTN trials at UM Rogel Cancer Center (24.2%)
Table 1 Medication or Medication Classes Identified by Protocol Guidance as Drug-drug Interactions
Trial Exclusion Avoid Caution
S0711 Acid suppression therapy (PPI, H2RA,
antacida)




S0528 Acid suppression therapy (PPI, H2RA,
antacida)
CYP3A4 inhibitors, CYP3A4 inducers Warfarin
PPI proton pump inhibitor, H2RA histamine H2 antagonists
aantacids were permitted for use if administration separated by 2 h from dasatinib or 1 h from lapatinib per the protocols
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[16] and within the ranges previously reported in pa-
tients with cancer (16–41%) [3–6]. Direct comparison of
these rates should be done cautiously as the prevalence
of DDI is largely determined by the interaction potential
of the agents used in the trials included in the analysis.
This analysis included two trials of agents with numer-
ous DDI, whereas our prior analysis included subjects
enrolled in 35 trials with a variety of trial agents and
DDI potential. Nevertheless, these findings suggest that
the ineffectiveness of DDI screening for oncology clinical
trial enrollment is not limited to a single or subset of in-
stitutions but is a systemic issue across sites. Based on
manual pharmacist review, 7% of subjects had a DDI
that was considered clinically relevant, further support-
ing the conclusion that improved DDI screening is ne-
cessary to prevent harm in clinical trial subjects and
ensure accuracy of trial data.
The vast majority of DDI detected in these trial sub-
jects were DDI that prevent drug absorption [17]. Ab-
sorption DDI are common for oral medications, which
are being used more often in cancer treatment due to
their improved convenience over parenteral administra-
tion [18]. Dasatinib absorption decreases with increasing
pH [19], consequently, acid suppression therapy (e.g.,
PPIs, H2RAs, and antacids) decreases absorption of
dasatinib leading to an AUC decrease of between 43 and
Fig. 1 Prevalence of Clinically Relevant Interactions from Lexicomp® and Protocol-Guided Screening. a. Protocol-guided screening detected drug-
drug interactions (DDI) in 18.6% of subjects. b. Lexicomp® detected DDI in 28.7% of subjects. The same subset of interactions detected by
protocol-guided screening and Lexicomp® were considered clinically relevant
Table 2 Drug-drug Interaction Prevalence
Primary analysis
Study ID Protocol: Exclude Protocol: Avoid Protocol: Caution Lexicomp® Clinically Relevant
DDI At Study Enrollment S0711 12.0% (10/83) 6.0% (5/83) 2.4% (2/83) 55.4% (46/83) 12.0% (10/83)
S0528 11.9% (10/84) 3.6% (3/84) 6.0% (5/84) 2.4% (2/84) 2.4% (2/84)
DDI Added During Study S0711 13.3% (11/83) 6.0% (5/83) 2.4% (2/83) 20.5% (17/83) 13.3% (11/83)
S0528 3.6% (3/84) 0.0% (0/84) 0.0% (0/84) 0.0% (0/84) 0.0% (0/84)
Secondary analysis
Study ID Protocol: Exclude Protocol: Avoid Protocol: Caution Lexicomp® Clinically Relevant
DDI At Study Enrollment S0711 22.9% (19/83) 6.0% (5/83) 2.4% (2/83) 55.4% (46/83) 22.9% (19/83)
S0528 11.9% (10/84) 3.6% (3/84) 6.0% (5/84) 2.4% (2/84) 2.4% (2/84)
DDI Added During Study S0711 15.7% (13/83) 6.0% (5/83) 2.4% (2/83) 20.5% (17/83) 15.7% (13/83)
S0528 6.0% (5/84) 0.0% (0/84) 0.0% (0/84) 0.0% (0/84) 0.0% (0/84)
DDI drug-drug interaction
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61% [11]. Reduced drug absorption leads to lower sys-
temic concentrations that could cause dasatinib treat-
ment efficacy to be decreased, as has been shown for
erlotinib and pazopanib [12, 13, 20]. This DDI is particu-
larly concerning given that the primary objective of
S0711 was to investigate the pharmacokinetics of dasati-
nib. This is just one of many possible scenarios where
ineffective DDI screening can meaningfully affect the ac-
curacy of the data collected within a clinical trial.
The high DDI prevalence in oncology trial subjects is
likely due to the lack of standard DDI screening proce-
dures during trial enrollment eligibility assessment [21].
In our prior survey of SWOG sites, most sites reported
that DDI screening relies primarily on DDI guidance
within the trial protocol and approximately half of sites
indicated that DDI screening is only conducted for DDI
that are explicit trial exclusion criterion [14]. Despite
sites self-reported reliance on protocols and particular
attention to exclusion criteria, in this analysis 12% of
subjects had DDI at enrollment that warranted trial ex-
clusion and 7% had a medication added during the trial
that warranted trial exclusion. This is perhaps the stron-
gest evidence of the inadequacy of the current systems
for DDI screening within oncology clinical trials. One
solution that has been proposed is to have pharmacist-
led comprehensive DDI screening for all oncology clin-
ical trial subjects [21], however, only 17% surveyed
SWOG sites reported pharmacists currently conduct
DDI screening. Most sites rely on clinical research coor-
dinators (56%) and study nurses (45%) who may have in-
sufficient knowledge and training on DDI [22, 23], and
pharmacist-led DDI screening likely is not given the lack
of pharmacists at up to 6% of sites that enroll subjects
on SWOG clinical trials [14]. An alternative approach
that we have advocated is to deploy a DDI screening tool
designed specifically to assist clinical trial staff with
screening for DDI for trial subjects [24]. Standardizing
DDI screening procedures for clinical trial subjects, ei-
ther through pharmacist involvement [25] or developing
a point of care tool, could dramatically improve the ef-
fectiveness and efficiency of DDI screening, yielding sig-
nificant benefits to trial subjects, staff, and investigators.
A limitation of this study is that only two trials were
included. Few SWOG protocols require collection of
concomitant medication information, limiting the avail-
ability of the data necessary to more comprehensively in-
vestigate the prevalence of DDI in SWOG trial subjects.
Additionally, the medication lists could not be further
verified from what was recorded as part of the original
study protocol. The medication lists were likely collected
by multiple individuals across trial sites, and it is pos-
sible inaccuracies exist. The concomitant medication
data did not specify administration times, so it is un-
known whether antacid interactions should have been
included. Antacids accounted for 50% of the DDI that
were classified as exclusion criteria or clinically relevant,
consequently, our estimated DDI prevalence is some-
what sensitive to whether it can be assumed that timing
of antacid administration was appropriate. Additionally,
some subjects had multiple strengths or routes of ad-
ministration of the same medication. These were treated
as individual DDI occurrences since the route and dose
of medications can impact the likelihood of a DDI. Fi-
nally, we used our standard approach of manual review
by a pharmacist to determine DDI clinical relevance;
however, slightly different prevalence estimates would
likely have been obtained if clinical relevance was deter-
mined by a different pharmacist.
Conclusions
DDI in clinical trial subjects have the potential to ad-
versely affect subject safety and compromise trial data
accuracy. Our results confirm a high prevalence of DDI
in subjects enrolled on SWOG clinical trials, further
supporting the need for improvements to DDI screening
procedures, particularly for trials of drugs that have high
DDI potential including oral anti-cancer agents.
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